400 related articles for article (PubMed ID: 28505977)
1. Hippocampal and Clinical Trajectories of Mild Cognitive Impairment with Suspected Non-Alzheimer's Disease Pathology.
Chung JK; Plitman E; Nakajima S; Caravaggio F; Iwata Y; Gerretsen P; Kim J; Takeuchi H; Shinagawa S; Patel R; Chakravarty MM; Graff-Guerrero A;
J Alzheimers Dis; 2017; 58(3):747-762. PubMed ID: 28505977
[TBL] [Abstract][Full Text] [Related]
2. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study.
Burnham SC; Bourgeat P; Doré V; Savage G; Brown B; Laws S; Maruff P; Salvado O; Ames D; Martins RN; Masters CL; Rowe CC; Villemagne VL;
Lancet Neurol; 2016 Sep; 15(10):1044-53. PubMed ID: 27450471
[TBL] [Abstract][Full Text] [Related]
3. Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology.
Schreiber S; Schreiber F; Lockhart SN; Horng A; Bejanin A; Landau SM; Jagust WJ;
JAMA Neurol; 2017 Jun; 74(6):650-659. PubMed ID: 28319241
[TBL] [Abstract][Full Text] [Related]
4. The Effects of Cortical Hypometabolism and Hippocampal Atrophy on Clinical Trajectories in Mild Cognitive Impairment with Suspected Non-Alzheimer's Pathology: A Brief Report.
Chung JK; Plitman E; Nakajima S; Caravaggio F; Shinagawa S; Iwata Y; Gerretsen P; Kim J; Takeuchi H; Patel R; Chakravarty MM; Strafella A; Graff-Guerrero A;
J Alzheimers Dis; 2017; 60(2):341-347. PubMed ID: 28826178
[TBL] [Abstract][Full Text] [Related]
5. Regional patterns of gray matter volume, hypometabolism, and beta-amyloid in groups at risk of Alzheimer's disease.
Wirth M; Bejanin A; La Joie R; Arenaza-Urquijo EM; Gonneaud J; Landeau B; Perrotin A; Mézenge F; de La Sayette V; Desgranges B; Chételat G
Neurobiol Aging; 2018 Mar; 63():140-151. PubMed ID: 29203090
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal β-Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology.
Gordon BA; Blazey T; Su Y; Fagan AM; Holtzman DM; Morris JC; Benzinger TL
JAMA Neurol; 2016 Oct; 73(10):1192-1200. PubMed ID: 27548756
[TBL] [Abstract][Full Text] [Related]
7. A Multi-Cohort Study of ApoE ɛ4 and Amyloid-β Effects on the Hippocampus in Alzheimer's Disease.
Khan W; Giampietro V; Banaschewski T; Barker GJ; Bokde AL; Büchel C; Conrod P; Flor H; Frouin V; Garavan H; Gowland P; Heinz A; Ittermann B; Lemaître H; Nees F; Paus T; Pausova Z; Rietschel M; Smolka MN; Ströhle A; Gallinat J; Vellas B; Soininen H; Kloszewska I; Tsolaki M; Mecocci P; Spenger C; Villemagne VL; Masters CL; Muehlboeck JS; Bäckman L; Fratiglioni L; Kalpouzos G; Wahlund LO; Schumann G; Lovestone S; Williams SC; Westman E; Simmons A; ; ;
J Alzheimers Dis; 2017; 56(3):1159-1174. PubMed ID: 28157104
[TBL] [Abstract][Full Text] [Related]
8. Topographical APOE ɛ4 Genotype Influence on Cerebral Metabolism in the Continuum of Alzheimer's Disease: Amyloid Burden Adjusted Analysis.
Seo EH; Kim SH; Park SH; Kang SH; Choo IH;
J Alzheimers Dis; 2016 Sep; 54(2):559-68. PubMed ID: 27567846
[TBL] [Abstract][Full Text] [Related]
9. The combination of apolipoprotein E4, age and Alzheimer's Disease Assessment Scale - Cognitive Subscale improves the prediction of amyloid positron emission tomography status in clinically diagnosed mild cognitive impairment.
Ba M; Ng KP; Gao X; Kong M; Guan L; Yu L;
Eur J Neurol; 2019 May; 26(5):733-e53. PubMed ID: 30561868
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.
Portelius E; Zetterberg H; Skillbäck T; Törnqvist U; Andreasson U; Trojanowski JQ; Weiner MW; Shaw LM; Mattsson N; Blennow K;
Brain; 2015 Nov; 138(Pt 11):3373-85. PubMed ID: 26373605
[TBL] [Abstract][Full Text] [Related]
11. Relationship Between Body Mass Index, ApoE4 Status, and PET-Based Amyloid and Neurodegeneration Markers in Amyloid-Positive Subjects with Normal Cognition or Mild Cognitive Impairment.
Blautzik J; Kotz S; Brendel M; Sauerbeck J; Vettermann F; Winter Y; Bartenstein P; Ishii K; Rominger A;
J Alzheimers Dis; 2018; 65(3):781-791. PubMed ID: 28697560
[TBL] [Abstract][Full Text] [Related]
12. APOE allele frequencies in suspected non-amyloid pathophysiology (SNAP) and the prodromal stages of Alzheimer's Disease.
Hohman TJ; Dumitrescu L; Oksol A; Wagener M; Gifford KA; Jefferson AL;
PLoS One; 2017; 12(11):e0188501. PubMed ID: 29190651
[TBL] [Abstract][Full Text] [Related]
13. Sex differences in the association between AD biomarkers and cognitive decline.
Koran MEI; Wagener M; Hohman TJ;
Brain Imaging Behav; 2017 Feb; 11(1):205-213. PubMed ID: 26843008
[TBL] [Abstract][Full Text] [Related]
14. Interaction Between BDNF Val66Met and APOE4 on Biomarkers of Alzheimer's Disease and Cognitive Decline.
Stonnington CM; Velgos SN; Chen Y; Syed S; Huentelman M; Thiyyagura P; Lee W; Richholt R; Caselli RJ; Locke DEC; Lu B; Reiman EM; Su Y; Chen K
J Alzheimers Dis; 2020; 78(2):721-734. PubMed ID: 33044176
[TBL] [Abstract][Full Text] [Related]
15. Sex, amyloid, and APOE ε4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-characterized cohorts.
Buckley RF; Mormino EC; Amariglio RE; Properzi MJ; Rabin JS; Lim YY; Papp KV; Jacobs HIL; Burnham S; Hanseeuw BJ; Doré V; Dobson A; Masters CL; Waller M; Rowe CC; Maruff P; Donohue MC; Rentz DM; Kirn D; Hedden T; Chhatwal J; Schultz AP; Johnson KA; Villemagne VL; Sperling RA; ; ;
Alzheimers Dement; 2018 Sep; 14(9):1193-1203. PubMed ID: 29803541
[TBL] [Abstract][Full Text] [Related]
16. Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer's disease (DELCODE).
Jessen F; Spottke A; Boecker H; Brosseron F; Buerger K; Catak C; Fliessbach K; Franke C; Fuentes M; Heneka MT; Janowitz D; Kilimann I; Laske C; Menne F; Nestor P; Peters O; Priller J; Pross V; Ramirez A; Schneider A; Speck O; Spruth EJ; Teipel S; Vukovich R; Westerteicher C; Wiltfang J; Wolfsgruber S; Wagner M; Düzel E
Alzheimers Res Ther; 2018 Feb; 10(1):15. PubMed ID: 29415768
[TBL] [Abstract][Full Text] [Related]
17. Suspected non-AD pathology in mild cognitive impairment.
Wisse LEM; Butala N; Das SR; Davatzikos C; Dickerson BC; Vaishnavi SN; Yushkevich PA; Wolk DA;
Neurobiol Aging; 2015 Dec; 36(12):3152-3162. PubMed ID: 26422359
[TBL] [Abstract][Full Text] [Related]
18. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.
Kerbler GM; Fripp J; Rowe CC; Villemagne VL; Salvado O; Rose S; Coulson EJ;
Neuroimage Clin; 2015; 7():105-13. PubMed ID: 25610772
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal change of biomarkers in cognitive decline.
Lo RY; Hubbard AE; Shaw LM; Trojanowski JQ; Petersen RC; Aisen PS; Weiner MW; Jagust WJ;
Arch Neurol; 2011 Oct; 68(10):1257-66. PubMed ID: 21670386
[TBL] [Abstract][Full Text] [Related]
20. Dissociable influences of
Ge T; Sabuncu MR; Smoller JW; Sperling RA; Mormino EC;
Neurology; 2018 May; 90(18):e1605-e1612. PubMed ID: 29592889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
